AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of 202.83 billion. The enterprise value is 227.86 billion.
| Market Cap | 202.83B |
| Enterprise Value | 227.86B |
Important Dates
The next estimated earnings date is Thursday, February 6, 2025.
| Earnings Date | Feb 6, 2025 |
| Ex-Dividend Date | Aug 8, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 31.23.
| PE Ratio | 31.23 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.07, with an EV/FCF ratio of 23.75.
| EV / Earnings | 35.08 |
| EV / Sales | 4.76 |
| EV / EBITDA | 13.07 |
| EV / EBIT | 17.85 |
| EV / FCF | 23.75 |
Financial Position
The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.77.
| Current Ratio | 0.93 |
| Quick Ratio | 0.71 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | 3.30 |
| Interest Coverage | 10.12 |
Financial Efficiency
Return on equity (ROE) is 16.66% and return on invested capital (ROIC) is 12.28%.
| Return on Equity (ROE) | 16.66% |
| Return on Assets (ROA) | 8.50% |
| Return on Capital (ROIC) | 12.28% |
| Revenue Per Employee | 569,588 |
| Profits Per Employee | 72,247 |
| Employee Count | 89,900 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.63 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.34% in the last 52 weeks. The beta is 0.17, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +1.34% |
| 50-Day Moving Average | 137.17 |
| 200-Day Moving Average | 148.85 |
| Relative Strength Index (RSI) | 46.02 |
| Average Volume (20 Days) | 3,379 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of 51.21 billion and earned 6.50 billion in profits. Earnings per share was 4.15.
| Revenue | 51.21B |
| Gross Profit | 42.30B |
| Operating Income | 13.67B |
| Pretax Income | 7.92B |
| Net Income | 6.50B |
| EBITDA | 18.39B |
| EBIT | 13.67B |
| Earnings Per Share (EPS) | 4.15 |
Balance Sheet
The company has 4.93 billion in cash and 31.61 billion in debt, giving a net cash position of -26.68 billion.
| Cash & Cash Equivalents | 4.93B |
| Total Debt | 31.61B |
| Net Cash | -26.68B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 40.81B |
| Book Value Per Share | 26.27 |
| Working Capital | -1.77B |
Cash Flow
In the last 12 months, operating cash flow was 11.33 billion and capital expenditures -1.74 billion, giving a free cash flow of 9.59 billion.
| Operating Cash Flow | 11.33B |
| Capital Expenditures | -1.74B |
| Free Cash Flow | 9.59B |
| FCF Per Share | n/a |
Margins
Gross margin is 82.61%, with operating and profit margins of 26.70% and 12.68%.
| Gross Margin | 82.61% |
| Operating Margin | 26.70% |
| Pretax Margin | 15.47% |
| Profit Margin | 12.68% |
| EBITDA Margin | 35.92% |
| EBIT Margin | 26.70% |
| FCF Margin | 18.73% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 0.74%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 0.74% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 71.25% |
| Buyback Yield | -0.22% |
| Shareholder Yield | 0.52% |
| Earnings Yield | 3.17% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.02.
| Altman Z-Score | 3.02 |
| Piotroski F-Score | n/a |